v3.25.2
Segment Information (Tables)
6 Months Ended
Jun. 30, 2025
Segment Information  
Schedule of segment revenue, segment loss, and significant segment expenses

Three Months Ended June 30, 

Six Months Ended June 30, 

2025

2024

2025

2024

Revenues:

Product sales, net

$

6,517

$

$

6,517

$

Service revenue, net

2,320

3,659

5,440

6,631

Total revenue

8,837

3,659

11,957

6,631

Cost of product sales

205

205

Cost of service revenue

1,292

1,493

2,809

2,960

Program expenses (1)

YUTREPIA

14,661

4,392

24,419

11,022

L606

2,793

1,657

6,061

3,235

Generic Treprostinil

125

241

276

444

Total program expenses

17,579

6,290

30,756

14,701

Non-program expenses (2)

 

5,835

 

7,735

 

9,605

 

14,085

Personnel, including stock-based compensation

21,431

15,338

41,512

30,883

Loss from operations

 

(37,505)

 

(27,197)

 

(72,930)

 

(55,998)

Other income (expense), net

 

(4,074)

 

(1,471)

 

(7,016)

 

(2,753)

Net loss

$

(41,579)

$

(28,668)

$

(79,946)

$

(58,751)

(1)Includes external research and development and selling, general and administrative expenses
(2)Includes professional service fees, facilities & infrastructure expenses, insurance, depreciation & amortization, and other corporate expenses